Moderate Growth in the Epilepsy Market is Expected from 2012 to 2022, According to a New Study on ASDReports

Friday 3 October 2014, Amsterdam

Market Research Report Press Release The global epilepsy market was valued at an estimated $4.2 billion in 2012. GlobalData expects the market to grow to $5.35 billion by 2022, with more than 50% of sales coming from the US. Major drivers of market growth over this forecast period will include:
  • Introduction of novel antiepileptic drugs (AEDs) with higher prices in the US and European Union (EU)
  • Introduction of the newer drugs into the Asian market, particularly in Japan
  • Increasing access to epilepsy pharmacotherapy by the populations of India and China 
Major barriers to the growth of the epilepsy market will include:
  • A crowded marketplace, which currently comprises more than 20 AEDs, many of which are available in generic form, resulting in individual drugs struggling to distinguish themselves
  • Concerns over decreasing healthcare costs as part of government austerity measures, which will impede market growth, particularly in Europe
  • Generic erosion of branded drug sales following small-molecule patent and marketing exclusivity expiries, particularly affecting Vimpat (lacosamide) and Lyrica (pregabalin)
PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

Publish date : December 2013
Report code : ASDR-150125
Pages : 306

ASDReports.com Media contact: S. Koopman - Marketing and Communications

ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : stefan.koopman@asdreports.com

 back to News